Calcimedica, INC 8-K filings

CalciMedica's Phase 2b CARPO trial of Auxora in acute pancreatitis met its primary objective, demonstrating a statistically significant dose response in reducing time to solid food tolerance and severe organ failure.

CalciMedica reported its first quarter 2024 financial results, highlighted by the completion of enrollment in a Phase 2b trial and progress in other clinical programs.

CalciMedica has dismissed Ernst & Young as its independent auditor and engaged Moss Adams for the fiscal year ending December 31, 2024.

CalciMedica has increased the maximum aggregate offering price of its common stock under an existing at-the-market offering agreement to $17,068,386.

CalciMedica reported its 2023 financial results, highlighted clinical trial progress, and secured funding to extend its operational runway into the second half of 2025.

CalciMedica has received FDA clearance for a Phase 2 trial of Auxora in acute kidney injury and anticipates data readouts for multiple trials in 2024 and 2025.

CalciMedica has announced a private placement to raise up to $55 million, including $20.4 million upfront, to fund clinical trials for its drug candidate Auxora.

CalciMedica has announced a private placement to raise up to $55 million to fund its clinical trials for Auxora in acute pancreatitis and acute kidney injury.